Board Change

RNS Number : 5943K

Retroscreen Virology Group PLC

26 June 2014

 



For immediate release 07.00: 26 June 2014

RETROSCREEN VIROLOGY GROUP PLC

("Retroscreen" or the "Company")

BOARD CHANGE

Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO human challenge models of disease, announces that, as a consequence of stepping down from the Board of IP Group plc, Charles Winward has resigned as a Director of the Company and will leave the Board with immediate effect.

Charles Winward joined Retroscreen Virology Limited as the Board representative of IP2IPO Services Limited in early 2009 and became a Non-Executive Director of the Company on 3 April 2012.  Charles has played a crucial role in transforming Retroscreen from an academic spin-out to a commercial enterprise and guiding the Company through its stock market listing.

Retroscreen is actively broadening its capabilities to exploit its unique hVIVO technology platform and the Board is evolving, as evidenced by other recently announced Board Changes.  The Company expects to announce a new Non-Executive Director in the near future.

Kym Denny, Chief Executive Officer, commented, "I would like to thank Charlie for his significant contribution, advice and support in helping Retroscreen become a high growth, publically listed company.  I wish him well for the future."

For further information please contact:

Retroscreen Virology Group plc                                                         [phone]

Kym Denny (CEO)

Graham Yeatman (FD)

Numis Securities Limited                                                                   [phone]

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

Notes to Editors:

Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing UK life sciences company pioneering a technology platform called hVIVO which uses human models of disease involving healthy volunteers to study new drugs and investigate disease in a safe, controlled environment.

Retroscreen has established itself as the world leader in this field through the provision of clinical services to third party study sponsors.  To date, the company has conducted over 35 clinical studies, involving more than 1700 volunteers for a range of leading industry, governmental and academic clients.

However, Retroscreen's hVIVO platform has a much wider application in helping to understand illness better because the Company believes that the best way to understand human disease is by studying it in humans, not laboratory models.

 

END

 

 

BOAQKADQPBKKQAB